← Back to Search

Monoclonal Antibodies

Infliximab for Inflammatory Bowel Disease

Phase 4
Waitlist Available
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Study Summary

This trial will test whether a common medicine for inflammatory bowel disease can be given faster, without affecting safety or effectiveness.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with acute infusion reaction as assessed by the nursing staff of the infusion unit
Secondary outcome measures
Cost saving analysis
Effect of concomitant immunomodulators and pre-medications on rate of infusion reactions

Side effects data

From 2020 Phase 4 trial • 42 Patients • NCT03006393
52%
Laceration
38%
Headache
24%
Bruises
19%
Sore throat
14%
Muscle tension
10%
Heartburn
10%
Fatigue
10%
Change in urination
10%
Nausea
10%
Dizziness
10%
Itchiness
5%
Menstruation
5%
Pain in joints
5%
Stomach ache
5%
Syncope
5%
Migraine
5%
Chest pain
5%
Swelling
5%
Bloody stool
5%
Pain in leg
5%
Allergies
5%
Change in blood pressure
5%
Vertigo
5%
Change in appetite
5%
Numbness
5%
Motor vehicle accident
100%
80%
60%
40%
20%
0%
Study treatment Arm
Infliximab
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: 1-hour infusion of infliximabExperimental Treatment1 Intervention
1 hour infusion of infliximab
Group II: 2-hour infusion of infliximabActive Control1 Intervention
2 hour infusion of infliximab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Infliximab
FDA approved

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,937 Previous Clinical Trials
2,299,602 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Infliximab an acceptable treatment option with minimal risk?

"Given that Infliximab is an approved treatment, its safety rating has been assessed at 3."

Answered by AI

Are researchers still accepting participants for this experiment?

"According to clinicaltrials.gov, this particular investigation is not currently enrolling new participants. The trial was first posted on August 1st 2020 and last edited in late August 2022; however, there are still 155 other medical studies actively seeking patients at present."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Safety of Reduced Infliximab Infusion Time
Chien-Huan Chen 2020. "Safety of Reduced Infliximab Infusion Time". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05340764.
~21 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top